GSK joins up with Aspen in Japanese venture; Roche's Lucentis on fast track for new diabetic retinopathy use;

@FiercePharma: Top-read in FP Weds: Novartis, GSK shake up executive ranks as overhaul continues. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI, this week's issue of FiercePharmaMarketing is here. And you can subscribe here. | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) inked a deal with South Africa-based Aspen Pharmacare to market mature products and new authorized generics in Japan. Report

> Roche's ($RHHBY) eye drug Lucentis won priority review at the FDA for a new use in diabetic retinopathy. Release

> Bristol-Myers Squibb ($BMY) said it has settled all U.S. patent litigation on its HIV drug Sustiva, giving the drug exclusivity through December 2017. Release

> Hospira ($HSP) recalled one lot of the high-powered antibiotic vancomycin because of potential temperature changes that could have affected the drug. Release

> India's Cipla said it would collaborate with Teva Pharmaceuticals ($TEVA) to sell Teva's drugs in South Africa, via a subsidiary, Medpro Pharmaceuticals. Report

> A headhunting firm sued Novartis Consumer Health ($NVS) for breach of contract, saying the drugmaker avoided paying $578,000 owed for executive search services. Report (reg. req.)

> Ironwood Pharmaceuticals ($IRWD) and Actavis ($ACT) are rolling out data on their gastrointestinal drug linaclotide, sold as Linzess in the U.S. and Constella in the EU. Release

Medical Device News

@FierceMedDev: Histogenics files for IPO, as Autogenomics refiles again. Article | Follow @FierceMedDev

@VarunSaxena2: HillaryClinton says we have to review +s and -s of device tax. An expected non-answer. | Follow @VarunSaxena2

@EmilyWFierce: Third time's a charm? FDA panel recommends Boston Scientific's Watchman device by a slim margin. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: With $RHHBY's Herceptin, green tea component doubles drug accumulation in #cancer cells. More | Follow @MichaelGFierce

> Boston Scientific wins positive recommendation from FDA panel for stroke-fighting Watchman device. More

> Stealth surgical reconstruction startup Tela-Bio raises $45.4 million. Item

> CoheroHealth to pilot asthma inhaler sensor and app at Mount Sinai Medical Center. Article

Biotech News

@FierceBiotech: VC giant NEA recruits a biotech vet to join its ranks of dealmakers. Report | Follow @FierceBiotech

@JohnCFierce: Biotechs tap a swelling tide of investment cash to fund growing R&D ops--or, laissez les bon temps rouler. Story | Follow @JohnCFierce

@DamianFierce: Deal: $AUXL leaves $QLTI at the altar and accepts a $2.6B offer from $ENDP. Release | Follow @DamianFierce

@EmilyMFierce: Ebola genome browser launched to aid drug discovery. FierceBiotech Research story | Follow @EmilyMFierce

> Auxilium takes money, runs from inversion with $2.6B Endo deal. Report

> Shire's long-delayed ADHD drug hits another FDA speed bump. Article

Vaccines News

> Pfizer's meningitis B vaccine is effective when given with HPV jab. More

> Sanofi bird flu vax prompts immune response in PhII--but only with Novartis adjuvant. Story

> Biotechs angling for T-cell response in race for next-gen herpes vaccine. Article

> Takeda appoints new vax development head as Novartis' Oswald heads for the door. Report

> Could 'space bacteria' help create vaccines? Item

Pharma Manufacturing News

> Impax says $700M deal for Tower will help it deal with quality issues. More

> Hospira recalls drug because of storage glitch during shipping. Report

> France's Ceva has completed a sterile facility for vet drugs. Item

> Gerresheimer adjusts earnings forecast lower in wake of FDA crackdown. Article

> CSL announces $450M commitment to expand two of its plants. Story

And Finally... More states are allowing preschools to mandate flu vaccinations for their charges. Report (sub. req.)